Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIF Combined with Anlotinib in Platinum-Resistant Ovarian Cancer
NCT07075250Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Drug Delivery Systems
01
Overview
A Phase 4 trial of Compound Huangdai Tablet in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Peking University People's Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Compound Huangdai Tablet
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT07075250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075250.